Fundz Deep Dive
Everything you need to win Valneva SE — in one platform.
Who to reach, what to say, and why now on Valneva SE — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.
Get the full Deep Dive on Valneva SE — free.
One free Deep Dive, emailed to you. No spam; unsubscribe anytime.
Ready now? Choose your plan · Request a demo · Sign in
Engage writes the reply
Grounded in signals no one else has — tuned to their persona.
Signals no one else has
UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.
Verified contact + click-to-call
The decision-maker’s email and mobile — dial in-browser.
Valneva SE announces robust and lasting immune response in adolescents one year after single vaccination with its chikungunya vaccine IXCHIQ®.
Jan 20, 2025•over 1 year ago
Pays De La LoireManufacturingBiotechnologyHealth CareMedicalProduct Description
Valneva SE has revealed positive Phase 3 results for its single-dose chikungunya vaccine, IXCHIQ®, showing a 98.3% seroresponse rate one year post-vaccination among adolescents. This data supports regulatory submissions for age extension in the US, Europe, and Canada and could lead to market authorization in Brazil.
Related People
Suggested for you
Product Launch Insights
Based on market dataMarket expansion signals
New product launches often coincide with market expansion initiatives